Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for promoting bone formation

a bone-specific alkaline phosphatase and bone-specific technology, applied in the field of bone-specific alkaline phosphatase, can solve the problems of bone loss, inability to achieve the effect of such treatment, and the balance of constructive and destructive processes is tipped from equilibrium, so as to promote bone growth, prevent bone loss, and promote bone growth

Inactive Publication Date: 2008-03-06
BURKE STEVEN K
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a method for treating osteoporosis and promoting bone growth using amine polymers. These polymers are not associated with the calcification of non-bone tissues and are typically non-absorbable, which reduces the risk of systemic side effects. The method can enhance or preserve bone density in patients and is particularly useful for patients who are not suffering from hyperphosphatemia or hyperparathyroidism. The polymers disclosed in the patent can be used in the manufacture of a medicament for the treatment of bone-related conditions.

Problems solved by technology

Bone loss results when the balance of the constructive and destructive processes is tipped from equilibrium toward a loss of calcium and other bone components.
One typical treatment for osteoporosis is hormone replacement therapy, however, the efficacy of such treatment is in doubt (Hulley, S., et al.
All of the aforementioned antiresorptive agents currently approved for the treatment decrease bone resorption but do not induce new bone formation.
In addition, bisphosphonates can cause side effects involving the gastrointestinal tract.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for promoting bone formation
  • Method for promoting bone formation
  • Method for promoting bone formation

Examples

Experimental program
Comparison scheme
Effect test

example 1

Clinical Testing

Patient Studies

[0060] Protocols 1-7 for use of RenaGel® (Geltex Pharmaceuticals, Inc., Waltham, Mass.) in each of the haemodialysis patient studies are provided in the following references, respectively, the teachings of which are incorporated herein by reference in their entireties.

Protocol 1:

[0061] Chertow, G. M., Burke, S. K., Lazarus, J. M., Stenzel, K. H., Wombolt, D., Goldberg, D., Bonventre, J. V., and Slatopolsky, E., “Poly(allylamine hydrochloride) (RenaGel®): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure,”Am. J. Kid. Dis. 29: 66-71 (1997).

Protocol 2: [0062] Goldberg, D. I., Dillon, M. A., Slatopolsky, E. A., Garrett, B., Gray, J. R., Marbury, T., Weinberg, M., Wombolt, D., and Burke, S. K., “Effect of RenaGel, a non-absorbed, calcium- and aluminum-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients,”Nephrol. Dial. Transplant. 13: 2303...

example 2

[0075] Upon finding that there were effects on bone in the patients studied in Example 1, an additional analysis was conducted in the larger group of patients from the original study who had a baseline and 12 month bone density scan.

Results

[0076] The study groups (calcium and sevelamer) were well balanced by randomization. At baseline, there were no significant differences between groups for any biochemical parameter measured except for slightly higher HDL cholesterol in the group randomized to calcium compared (calcium 50±17 mg / dL vs. sevelamer 44±15 mg / dL, p=0.04).

[0077] Following the 12 months of treatment, the levels a number of biochemical markers were assayed in the patient groups. Serum phosphorus and calcium-phosphorus product were not significantly different between treatment groups. The group treated with sevelamer had on average higher iPTH, 1-84 PTH, alkaline phosphatase, bone specific alkaline phosphatase, osteocalcin, and HDL cholesterol. The sevelamer group had lo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
aliphaticaaaaaaaaaa
strengthaaaaaaaaaa
densityaaaaaaaaaa
Login to View More

Abstract

Amine polymers, particularly aliphatic amine polymers, are useful in the treatment and prevention of bone disease and in methods for promoting bone formation. Sevelemer, polyallylamine crosslinked with epichlorohydrin, which is sold under the tradename Renagel®, is the preferred polymer used in the invention.

Description

RELATED APPLICATIONS [0001] This application claims the benefit of U.S. Provisional Application No. 60 / 420,489, filed Oct. 22, 2002, and U.S. Provisional Application No. 60 / 443,937, filed Jan. 30, 2003. The entire teachings of the above applications are incorporated herein by reference.BACKGROUND OF THE INVENTION [0002] Osteoporosis is a progressive condition in which bones gradually lose their strength and density. An estimated 1 million older Americans suffer broken bones (typically wrist, spinal vertebrae and hips) because of osteoporosis. Women typically account for the vast majority of injuries caused by osteoporosis. [0003] Normally, bone is continuously removed by osteoclasts and is replaced with new bone that is produced by osteoblasts. Bone loss results when the balance of the constructive and destructive processes is tipped from equilibrium toward a loss of calcium and other bone components. Osteoporosis is typically caused by either environmental or genetic factors. Envir...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/785A61K31/74A61P19/08A61P19/10
CPCA61K31/785A61K31/74A61P19/08A61P19/10
Inventor BURKE, STEVEN K.
Owner BURKE STEVEN K
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com